Acute Lymphoblastic Leukemia
The latest news, research, and perspectives in acute lymphoblastic leukemia (ALL). The most common type of leukemia in children, ALL develops when bone marrow produces a large number of immature lymphoblasts that grow quickly and replace normal cells in the bone marrow.
Advertisement
Nicholas Freedman, DO, presented on symptom management and supportive care at the Tri-State Blood Cancer Conference.
More than 240 meetings were held with members of Congress as part of the ASCO 10th Annual Advocacy Summit.
Joseph G. Jurcic, MD on the journey to survivorship for adults with either AML or ALL.
Overall survival was also greater in the study comparing the treatments in ALL, AML, MDS, and mixed-phenotype acute leukemia.
Measurable residual disease has a prominent role in risk assessment, prognosis, and management decisions in T-ALL and B-ALL.
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
Advertisement
CTD402 will be studied in a single-arm, open-label, phase 1b/2 trial with a simplified dose-finding design.
The approval is based on the E1910 trial, which compared blinatumomab and consolidation chemotherapy with chemotherapy alone.
Therapy also in development for T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and mantle cell lymphoma.
The US cancer mortality rate has declined by 34%, but the incidence of leukemia and other malignancies is increasing.
A real-world study found blinatumomab plus ponatinib as more likely to be effective if used in earlier lines of therapy.
Issues addressed include mandatory versus optional biopsy, informed consent, and safety in both adult and pediatric patients.
A compound to assist CAR T-cell therapy by targeting and suppressing YTHDF2 is in development.
Continued treatment and follow-up of patients after the interim analysis demonstrate the durability of response to revumenib.
The approach demonstrated safety and produced response in B-ALL, DLBCL, follicular lymphoma, and MCL.
The approval is based on results of the FELIX trial, which evaluated the safety and efficacy of obe-cel.
The approval is based on results of the phase I/II AUGMENT-101 trial, where revumenib achieved a CR+CRh rate of 21%.
The interest in using quantitative tests to measure residual cancer cells continues to expand in the arena of blood cancers.
The one-year overall survival rate of 90%, and the MRD negativity rate was 94%.
The phase Ib/II FELIX trial found that obe-cel is effective for the treatment of relapsed or refractory adult B-cell ALL.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.